Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma
2012-004766-17Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Progression-free survival. Started Apr 2013; status: completed.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2012-004766-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004766-17.